Roche lines up at the FDA's 10-yard line with $1.7B Igny­ta buy­out

Can­cer drug pow­er­house Roche $RHH­BY has swooped in to buy Igny­ta $RXDX for $1.7 bil­lion, putting the phar­ma gi­ant in di­rect com­pe­ti­tion with Loxo On­col­o­gy $LOXO and its new part­ners at Bay­er.

Igny­ta has been grab­bing the at­ten­tion of a boom­ing field with its work in ROS1 and NTRK fu­sion-pos­i­tive tu­mors, win­ning the FDA’s break­through sta­tus last May. And it’s en­gaged in a piv­otal Phase II study for its lead drug en­trec­tinib that could put Roche on the 10 yard line at the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER